NasdaqCM - Nasdaq Real Time Price USD

Avid Bioservices, Inc. (CDMO)

Compare
10.54 +0.20 (+1.93%)
At close: November 5 at 4:00 PM EST
10.54 0.00 (0.00%)
After hours: November 5 at 4:03 PM EST
Loading Chart for CDMO
DELL
  • Previous Close 10.34
  • Open 10.17
  • Bid 10.49 x 100
  • Ask 10.57 x 100
  • Day's Range 10.15 - 10.54
  • 52 Week Range 4.07 - 12.48
  • Volume 349,997
  • Avg. Volume 737,881
  • Market Cap (intraday) 672.4M
  • Beta (5Y Monthly) 1.39
  • PE Ratio (TTM) --
  • EPS (TTM) -2.29
  • Earnings Date Dec 5, 2024 - Dec 9, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 13.50

Avid Bioservices, Inc. operates as a contract development and manufacturing organization for the biotechnology and biopharmaceutical industries in the United States. It provides process development and current good manufacturing practice clinical and commercial manufacturing services of biologics, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, regulatory submission and support, upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization services. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is based in Tustin, California.

www.avidbio.com

371

Full Time Employees

April 30

Fiscal Year Ends

Recent News: CDMO

View More

Performance Overview: CDMO

Trailing total returns as of 11/5/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

CDMO
62.15%
S&P 500
21.24%

1-Year Return

CDMO
62.40%
S&P 500
32.68%

3-Year Return

CDMO
68.14%
S&P 500
23.56%

5-Year Return

CDMO
99.62%
S&P 500
87.86%

Compare To: CDMO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: CDMO

View More

Valuation Measures

Annual
As of 11/4/2024
  • Market Cap

    659.64M

  • Enterprise Value

    832.22M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    4.60

  • Price/Book (mrq)

    11.25

  • Enterprise Value/Revenue

    5.85

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -101.27%

  • Return on Assets (ttm)

    -3.05%

  • Return on Equity (ttm)

    -115.84%

  • Revenue (ttm)

    142.36M

  • Net Income Avi to Common (ttm)

    -144.16M

  • Diluted EPS (ttm)

    -2.29

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    36.78M

  • Total Debt/Equity (mrq)

    353.77%

  • Levered Free Cash Flow (ttm)

    -201.62k

Research Analysis: CDMO

View More

Company Insights: CDMO

Research Reports: CDMO

View More

People Also Watch